The immunogenicity of chimeric antibodies
- PMID: 2584938
- PMCID: PMC2189553
- DOI: 10.1084/jem.170.6.2153
The immunogenicity of chimeric antibodies
Abstract
Mice were immunized with model xenogeneic (both the VH frameworks and the CH domains of human origin), chimeric (just VH frameworks human), or self antibodies, and the antiantibody responses were dissected. Only the self antibody did not elicit a response. A strong response was elicited by the most xenogeneic antibody with approximately 90% against the C and approximately 10% against the V. The anti-V response was not attenuated in the chimeric antibody, demonstrating that foreign VH frameworks can be sufficient to lead to a strong antiantibody response. The magnitude of this xenogeneic anti-VH response was similar to that of the allotypic response elicited by immunizing mice of the Igha allotype with an Ighb antibody. Thus, although chimerization can diminish antiantibody responses, attention should be paid both to V region immunogenicity and to polymorphism.
Similar articles
-
Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.J Immunol. 1986 Aug 15;137(4):1371-5. J Immunol. 1986. PMID: 2426362
-
Induction of "latent a2" allotype in a1a1 homozygous rabbits as the major part of a bidirectional immune response to immunization with anti-a2 antibody.J Immunol. 1984 Apr;132(4):1909-16. J Immunol. 1984. PMID: 6421928
-
Allogeneic manipulation of the GAT idiotypic cascade. Immunization of C57BL/6 mice by BALB/c anti-idiotypes stimulates similar strain-specific V genes as the original antigen.J Immunol. 1988 Aug 1;141(3):779-84. J Immunol. 1988. PMID: 3135311
-
Anti-allotype antibody response in mice: expression of a cross-reactive idiotype and its regulation by auto-anti-idiotypic antibodies in maternally allotype suppressed F1 hybrids.Prog Clin Biol Res. 1980;42:263-77. Prog Clin Biol Res. 1980. PMID: 6994111 Review.
-
Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.Arch Immunol Ther Exp (Warsz). 2001;49(6):407-15. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11814234 Review.
Cited by
-
Soluble Expression of Humanized Anti-CD20 Single Chain Antibody in Escherichia coli by Cytoplasmic Chaperones Co-expression.Avicenna J Med Biotechnol. 2018 Jul-Sep;10(3):141-146. Avicenna J Med Biotechnol. 2018. PMID: 30090206 Free PMC article.
-
Antibody engineering to develop new antirheumatic therapies.Arthritis Res Ther. 2009;11(3):225. doi: 10.1186/ar2594. Epub 2009 May 19. Arthritis Res Ther. 2009. PMID: 19490600 Free PMC article. Review.
-
Human antibody production in transgenic animals.Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):101-8. doi: 10.1007/s00005-014-0322-x. Epub 2014 Dec 3. Arch Immunol Ther Exp (Warsz). 2015. PMID: 25467949 Free PMC article. Review.
-
Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.Oncotarget. 2017 Apr 19;8(31):51238-51252. doi: 10.18632/oncotarget.17228. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881644 Free PMC article.
-
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Immunotherapy. 2016 Sep;8(9):1097-117. doi: 10.2217/imt-2016-0021. Immunotherapy. 2016. PMID: 27485082 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources